GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022

Rhea-AI Summary

Global Blood Therapeutics (GBT) announced it will report its first quarter 2022 financial results on May 4, 2022, after U.S. market close. A conference call will take place the same day at 4:30 p.m. ET to discuss these results and provide a business update. GBT focuses on developing treatments for sickle cell disease (SCD), highlighted by its FDA-approved drug Oxbryta. The company is also advancing its pipeline with a Phase 3 program for inclacumab and continues to explore new therapeutic targets.

Positive

• FDA-approved Oxbryta is a breakthrough treatment for SCD.
• Pipeline advancement with inclacumab in Phase 3 development.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close.

Management will host a conference call on Wednesday, May 4, 2022, at 4:30 p.m. ET to discuss first quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT’s website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the event.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650.410.3258
simmergut@gbt.com

Courtney Roberts (investors)
650.351.7881
croberts@gbt.com

 

FAQ

When will Global Blood Therapeutics report its Q1 2022 financial results?

Global Blood Therapeutics will report its Q1 2022 financial results on May 4, 2022.

What time is the conference call for GBT's financial results?

The conference call for GBT's financial results is scheduled for 4:30 p.m. ET on May 4, 2022.

What is the focus of Global Blood Therapeutics?

Global Blood Therapeutics focuses on developing treatments for sickle cell disease.

What is inclacumab's development status?

Inclacumab is currently in Phase 3 development for treating pain crises associated with sickle cell disease.

How can I access GBT's conference call?

You can access GBT's conference call by dialing 877-407-3982 or +1 201-493-6780, or via a live audio webcast on GBT's website.